Related Experiment Video
Updated: May 22, 2026

Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease
David A Elliott1, Woojin S Kim, Sarsha Gorissen
1Neuroscience Research Australia, Barker St., Randwick, Sydney, NSW 2031, Australia.
Abstract:
Mutations of the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson's disease (PD) and are associated with pleiomorphic neuropathology. We hypothesize that LRRK2 mediates its pathogenic effect through alternative splicing of neurodegeneration genes. Methods used in this study included western blotting analysis of subcellular protein fractions, exon-array analysis of RNA from cultured neuroblastoma cells transfected with LRRK2 expression vectors, and reverse-transcription polymerase chain reaction (RT-PCR) of RNA from cultured cells and postmortem tissue. Overexpression of the LRRK2 G2019S mutant resulted in a significant (2.6-fold; P = 0.020) decrease in nuclear transactive response DNA-binding protein 43 levels. Exon-array analyses revealed that wild-type LRRK2 had a significant effect on the expression of genes with nuclear (P < 10(-22) ) and cell-cycle functions (P < 10(-15) ). We replicated changes in gene expression in 30% of selected genes by quantitative RT-PCR. Overexpression of LRRK2 resulted in the altered splicing of two genes associated with PD, with an increased inclusion of exon 10 of microtubule-associated protein tau (1.7-fold; P = 0.001) and exon 5 of the alpha-synuclein (SNCA) gene (1.6-fold; P =0.005). Moreover, overexpression of LRRK2 (G2019S) and two mutant genes associated with neurodegeneration, TARDBP (M337V) and FUS (R521H), were associated with decreased inclusion out of the dystonin (DST) 1e precursor exons in SK-N-MC cells. Altered splicing of SNCA (1.9-fold; P < 0.001) and DST genes (log(2) 2.3-fold; P = 0.005) was observed in a cohort of PD, compared with neurologically healthy, brains. This suggests that aberrant RNA metabolism is an important contributor to idiopathic PD.
Insights
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are linked to Parkinson's disease (PD). This study found LRRK2 influences alternative splicing in neurodegeneration genes, suggesting RNA metabolism alterations contribute to PD.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson's disease (PD).
- LRRK2 mutations are associated with diverse neuropathological findings.
- The precise mechanisms by which LRRK2 mutations contribute to PD pathogenesis remain incompletely understood.
Purpose of the Study:
- To investigate the hypothesis that LRRK2 mediates its pathogenic effects through alternative splicing of neurodegeneration-associated genes.
- To explore the role of LRRK2 in regulating gene expression and RNA splicing patterns relevant to Parkinson's disease.
Main Methods:
- Western blotting to analyze subcellular protein fractions.
- Exon-array analysis of RNA from neuroblastoma cells transfected with LRRK2 expression vectors.
- Reverse-transcription polymerase chain reaction (RT-PCR) on cultured cells and postmortem Parkinson's disease brain tissue.
Main Results:
- Overexpression of LRRK2 (G2019S mutant) significantly decreased nuclear transactive response DNA-binding protein 43 (TRDDPB) levels.
- LRRK2 significantly affected the expression of genes involved in nuclear functions and cell-cycle regulation.
- Altered splicing of microtubule-associated protein tau (MAPT) and alpha-synuclein (SNCA) genes was observed upon LRRK2 overexpression, and in postmortem PD brains.
Conclusions:
- Aberrant RNA metabolism, specifically altered alternative splicing, is implicated as a significant contributor to idiopathic Parkinson's disease.
- LRRK2 plays a role in regulating RNA splicing of key genes associated with neurodegeneration.
- These findings highlight potential therapeutic targets within RNA processing pathways for Parkinson's disease treatment.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Neural Regulation

